Corynoxine, isolated from Uncaria rhynchophylla, promotes the clearance of alpha-synuclein

Corynoxine, isolated from Uncaria rhynchophylla, promotes the clearance of alpha-synuclein
www.ncbi.nlm.nih.gov/pubmed/24522518

Corynoxine, isolated from Uncaria rhynchophylla, promotes the clearance of alpha-synuclein via mTOR pathway [R].

use of Uncaria rhynchophylla, known as “Gou-teng” herb extract

examine.com/supplements/uncaria-rhynchophylla/

www.ncbi.nlm.nih.gov/pubmed/29940559

buy uncaria-rhynchophylla:

www.aliexpress.com/item/100-1000g-Wild-High-quality-Uncaria-Uncaria-rhynchophylla-gouteng-Extract-ramuli-umcariae-cum-uncis-gou-teng/32974275356.html?spm=2114.search0104.8.14.2ad83b31Ekk5f4

buy Corynoxine:

www.alibaba.com/trade/search?fsb=y&IndexArea=product_en&CatId=&SearchText=Corynoxine

 

 

mutant (A53T) α-synuclein exhibit impaired autonomic regulation of heart rate characterized by elevated resting heart rate

Mutations in α-synuclein cause some cases of familial PD. Several lines of transgenic mice that overexpress wild type or mutant human α-synuclein exhibit progressive accumulation of α-synuclein in neurons, motor dysfunction and death (). Mice expressing mutant (A53T) α-synuclein exhibit impaired autonomic regulation of heart rate characterized by elevated resting heart rate associated with accumulation of α-synuclein aggregates in the brainstem and reduced parasympa-thetic (cardiovagal) tone (). Maintenance of the α-synuclein mutant mice on ADF reversed the autonomic deficit, whereas a high fat diet exacerbated the autonomic deficit (). Consistent with the latter findings, a high fat diet hastened the onset of motor dysfunction and brainstem pathology in another line of α-synuclein mutant mice, which was associated with reduced activity of kinases known to be involved in neurotrophic factor signaling (). In addition to enhancement of neurotrophic factor/BDNF signaling, IF may counteract PD-related pathogenic processes by stimulating autophagy. Indeed, inhibition of mTOR with rapamycin, which stimulates autophagy, reduced oxidative stress and synaptic damage, and improved motor function in a α-synuclein accumulation-based mouse model of PD ().

full article intermittent fasting >> 

Magnesium

www.naturalstacks.com/blogs/news/magnesium

www.naturalnews.com/046401_magnesium_dietary_supplements_nutrient_absorption.html

magnesium deficiency can cause hreart palpatation and also calcification of heart and blood vessle

general association between magnesium and heart health www.ncbi.nlm.nih.gov/pmc/articles/PMC3957229/

 magnesium salts  could reduce the progress of aortic valve stenosis 

 

Forced exercise 35% improvement, motor learning ? upregulate dopamine

www.ncbi.nlm.nih.gov/pubmed/19131578/

www.ncbi.nlm.nih.gov/pmc/articles/PMC4744893/#s002

motor learning activated by stressor – speed, to adapt to the stressor,result is speed and performance when in speed

i assume it goes both ways and e.g. Zen meditation will slow onedown, also depresion/LH/static job

possible treatment -external speed (treadmill),external speed  /pulse measurement

————————–

I speculate that high intensity over continues period of time develops (up regulate) dopamine secretion. that includes brain games

Insulin Resistance, GLP-1 analogues, Incretin Mimetics for AD and PD

Brain
AD – See Bredesen

PD –
A pilot study in PD patients testing a GLP-1 receptor agonist that is currently on the market as a treatment for type 2 diabetes (exendin-4, Byetta) also showed encouraging effects. Several other clinical trials are currently ongoing in AD patients, testing another GLP-1 analogue that is on the market (liraglutide, Victoza). Recently, a third GLP-1 receptor agonist has been brought to the market in Europe (Lixisenatide, Lyxumia), which also shows very promising neuroprotective effects. This review will summarise the range of these protective effects that those drugs have demonstrated. GLP-1 analogues show promise in providing novel treatments that may be protective or even regenerative in AD and PD, something that no current drug does.
Drugs developed for treatment of diabetes show protective effects in Alzheimer’s and Parkinson’s diseases.

Drugs developed for treatment of diabetes show protective effects inAlzheimer’s and Parkinson’s diseases – full text review

www.ncbi.nlm.nih.gov/pubmed/28927992

חקייני אינקרטין (Incretin Mimetics)

Heart:

Gut
See Ronda Patrick

 

related treatment option for PD  see https://1.getmanaged.online/nly01-halts-pd/

 

NLY01 halts PD

Similar drugs to NLY01 already approved by the Food and Drug Administration for the treatment of type 2 diabetes include exenatide, lixisenatide, liraglutide and dulaglutide, each of which can cost approximately $2,000 for a 90-day supply. NLY01 is a long-acting drug with improved the brain penetration compared to these approved drugs for diabetes.

www.sciencedaily.com/releases/2018/07/180702120505.htm

afforable:
dir.indiamart.com/impcat/liraglutide.html